ARTICLE | Clinical News
Capravirine (AG1549): Began Phase II/III trials
January 29, 2001 8:00 AM UTC
Pfizer Inc. (PFE), New York, N.Y. Product: Capravirine (AG1549) Business: Infectious diseases Therapeutic category: Viral replication Target: Reverse transcriptase Description: Non-nucleoside reverse ...